Osteoporosis and the growth hormone-insulin-like growth factor axis

Hormone Research

Volumn 58, Issue SUPPL. 3, 2002, Pages 49-55

  Geusens, Piet P M M ^a,b   Boonen, Steven ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HASSELT UNIVERSITY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Growth hormone; Hip fracture; Insulin like growth factor; Osteoporosis

Indexed keywords

ANABOLIC AGENT; GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; HUMAN GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN C;

ACROMEGALY; AGING; ARTHRALGIA; BONE DENSITY; BONE MASS; BONE TURNOVER; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; DYSPNEA; EDEMA; GLUCOSE INTOLERANCE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEADACHE; HORMONAL THERAPY; HUMAN; HYPOGLYCEMIA; INTRACRANIAL HYPERTENSION; MUSCLE FATIGUE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PAPILLEDEMA; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYNCOPE; WEIGHT GAIN; ADULT; ANIMAL; BONE DISEASE; CHILD; PHYSIOLOGY;

ADULT; AGING; ANIMALS; BONE DISEASES; CHILD; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OSTEOPOROSIS; SOMATOMEDINS;

EID: 0036436767     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066483     Document Type: Review

References (68)

1. Bouillon R: Growth hormone and bone. Horm Res 1991;36(suppl 1):49-55.
2. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC: Growth hormone and bone. Endocr Rev 1998;19:55-79.
3. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P: The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001; 16:398-405.
4. Rosen CJ, Donahue LR: Insulin-like growth factors and bone: The osteoporosis connection revisited. Proc Soc Exp Biol Med 1998;219: 1-7.
5. Rosen CJ, Pollak M: Circulating IGF-I: New perspectives for a new century. Trends Endocrinol Metab 1999;10:136-141.
6. Andreassen TT, Melsen F, Oxlund H: The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged rats. J Bone Miner Res 1996;11:1094-1102.
7. Jorgensen PH, Bak B, Andreassen TT: Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with biosynthetic human growth hormone. Bone 1991;12:353-359.
8. Verhaeghe J, van Bree R, Van Herck E, Thomas H, Skottner A, Dequeker J, Mosekilde L, Einhorn TA, Bouillon R: Effects of recombinant human growth hormone and insulin-like growth factor-I, with or without 17β-estradiol, on bone and mineral homeostasis of aged ovariectomized rats. J Bone Miner Res 1996; 11:1723-1735.
9. Bak B, Andreassen TT: The effect of growth hormone on fracture healing in old rats. Bone 1991;12:151-4.
10. Dott NM, Fraser J: The influence of experimental pituitary and thyroid derangements upon the developmental growth of bone. Q J Exp Physiol (Suppl) 1923;13:107-108.
11. Charlton HM, Clark RG, Robinson IC, Goff AE, Cox BS, Bugnon C, Bloch BA: Growth hormone-deficient dwarfism in the rat: A new mutation. J Endocrinol 1988;119:51-58.
12. Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Birnberg NC, Evans RM: Dramatic growth of mice that develop from eggs microinjected with metallo-thionein-growth hormone fusion genes. Nature 1982;300:611-615.
13. Rosen HN, Chen V, Cittadini A, Greenspan SL, Douglas PS, Moses AC, Beamer WG: Treatment with growth hormone and IGF-I in growing rats increases bone mineral content but not bone mineral density. J Bone Miner Res 1995;10:1352-1358.
14. Bouillon R (ed): GH and Bone. London, OCC Ltd, 1998.
15. 3 and activity on human osteoblast-like cells in short-term cultures. Bone 1990;11:81-86.
16. Merriman HL, La Tour D, Linkhart TA, Mohan S, Baylink DJ, Strong DD: Insulin-like growth factor-I and insulin-like growth factor-II induce c-fos in mouse osteoblastic cells. Calcif Tissue Int 1990;46:258-262.
17. Wuster C, Rosen C: Growth hormone, insulin-like growth factors; in Marcus, Feldman, Kelsey (eds): Osteoporosis. New York, Academic Press, 2001.
18. Xuetzong Q, Gysin R, Mohan S, Baylink D: Bone growth factors; in Marcus, Feldman, Kelsey (eds): Osteoporosis. New York, Academic Press, 2001.
19. Hill PA, Tumber A, Meikle MC: Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology 1997;138:3849-3858.
20. Hill PA, Reynolds JJ, Meikle MC: Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Endocrinology 1995;136:124-131.
21. Riggs LR, Randall RV, Wahner HW, Jowsey J, Kelly PJ, Singh M: The nature of the metabolic bone disorder in acromegaly. J Clin Endocrinol 1972;34:543-551.
22. Lesse GP, Fraser WD, Farquharson R, Hipkin L, Vora JP: Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf) 1998;48:59-65.
23. Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR: Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 1993;76:1452-57.
24. Diamond T, Nery L, Pose S: Spinal and peripheral bone mineral densities in acromegaly. Ann Intern Med 1989;111:567-573.
25. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL: Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 1982;69: 1302-1309.
26. Wuster C: Growth hormone and bone metabolism. Acta Endocrinol (Copenh) 1993;128 (suppl 2):14-18.
27. Wuster C, Duckeck G, Ugurel A, Lojen M, Minne HW, Ziegler R: Bone mass of spine and forearm in osteoporosis and in German normals: Influences of sex, age and anthropometric parameters. Eur J Clin Invest 1992;22:366-370.
28. Delmas PD, Chatelain P, Malaval L, Bonne G: Serum bone GLA-protein in growth hormone-deficient children. J Bone Miner Res 1986;1: 333-338.
29. De Boer H, Blok GJ, van Lingen A, Teule GJ, Lips P, van der Veen EA: Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994;9: 1319-1326.
30. Kann P, Piepkorn B, Pfutzner A, Peipenburg R, Beyer J: Bone quality in GH-deficient adults. Acta Endocrinol 1993;128(suppl 2):60.
31. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997; 137:240-245.
32. Donahue LR, Hunter SJ, Sherblom AP, Rosen C: Age-related changes in serum insulin-like growth factor-binding proteins in women. J Clin Endocrinol Metab 1990;71:575-579.
33. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP: Association between insulin-like growth factor I and bone mineral density in older women and men: The Framingham Heart Study. J Clin Endocrinol Metab 1998;83:4257-4262.
34. Corpas E, Harman SM, Blackman MR: Human growth hormone and human aging. Endocr Rev 1993;14:20-39.
35. Boonen S, Aerssens J, Dequeker J, Nicholson P, Cheng X, Lowet G, Verbeke G, Bouillon R: Age-associated decline in human femoral neck cortical and trabecular content of insulin-like growth factor I. Potential implications for age-related (type II) osteoporotic fracture occurrence. Calcif Tissue Int 1997;61:173-178.
36. Nicolas V, Prewett A, Bettica P, Mohan S, Finkelman RD, Baylink DJ, Farley JR: Age-related decreases in insulin-like growth factor-I and transforming growth factor-β in femoral cortical bone from both men and women: Implications for bone loss with aging. J Clin Endocrinol Metab 1994;78:1011-1016.
37. Bonjour JP, Schurch MA, Chevalley T, Ammann P, Rizzoli R: Protein intake, IGF-1 and osteoporosis. Osteoporos Int 1997;7(suppl 3): S36-S42.
38. Dequeker J, Burssens A, Bouillon R: Dynamics of growth hormone secretion in patients with osteoporosis and in patients with osteoarthrosis. Horm Res 1982;16:353-356.
39. Garnero P, Sornay-Rendu E, Delmas PD: Low serum IGF-I and occurrence of osteoporotic fractures in postmenopausal women (letter). Lancet 2000;355:898-899.
40. Wuster C, Blum WF, Schlemilch S, Ranke MB, Ziegler R: Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. J Intern Med 1993;234:249-255.
41. Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ: Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 1999;14:2150-2158.
42. Ljunghall S, Johansson AG, Burman P, Kampe O, Lindh E, Karlsson FA: Low plasma levels of insulin-like growth factor 1 in male patients with idiopathic osteoporosis. J Intern Med 1992;232:59-64.
43. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, Bilezikian JP: Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997;82:2799-2805.
44. Kurland ES, Chan FK, Rosen CJ, Bilezikian JP: Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor I. J Clin Endocrinol Metab 1998;83: 2576-2579.
45. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A: Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 1996;81:3864-3870.
46. Carey DE, Goldberg B, Ratzan SK, Rubine KR, Rowe DW: Radioimmunoassay for type I procollagen in GHD children before and during treatment with GH. Pediatr Res 1985;19: 8-11.
47. Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G: Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993;122:37-45.
48. Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Moller J, Muller J, Skakkebaek NE, Christiansen JS: Long-term growth hormone treatment in growth hormone-deficient adults. Acta Endocrinol (Copenh) 1991;125:449-453.
49. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH: Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991; 70:688-694.
50. Van der Veen EA, Netelenbos JC: Growth hormone (replacement) therapy in adults: Bone and calcium metabolism. Horm Res 1990;33 (suppl 4):65-68.
51. Janssen YJ, Hamdy NA, Frolich M, Roelfsema F: Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83:2143-2148.
52. Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson BA: Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996;81:2865-2873.
53. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A: Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996;125:883-890.
54. Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J: Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 1998;48: 561-568.
55. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A: Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996;125(11):883-890.
56. Clanget C, Seck T, Hinke V, Wuster C, Ziegler R, Pfeilschifter J: Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf) 2001;55:93-99.
57. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
58. Marcus R, Butterfield G, Holloway L, Gilliland L, Baylink DJ, Hintz RL, Sherman BM: Effects of short-term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990;70:519-527.
59. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R: Effects of recombinant human growth hormone on metabolic indices, body composition and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994;79:470-479.
60. Rosen CJ and al: The RIGHT study: A randomized placebo controlled trial of rhGH in frail elderly. J Bone Miner 1999;14(suppl):208.
61. Kassem M, Brixen K, Blum WF, Mosekilde L, Eriksen EF: Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis. J Bone Miner Res 1994;9:1365-1370.
62. Holloway L, Kohlmeier L, Kent K, Marcus R: Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab 1997;82:1111-1117.
63. Van der Lely AJ, Lamberts SW, Jauch KW, Swierstra BA, Hertlein H, Danielle De Vries D, Birkett MA, Bates PC, Blum WF, Attanasio AF: Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol 2000; 143:585-592.
64. Ebeling PR, Jones JD, O'Fallon WM, Janes CH, Riggs BL: Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab 1993;77:1384-1387.
65. Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, Marcus R: Effects of recombinant insulin-like growth factor I and growth hormone on bone turnover in elderly women. J Bone Miner Res 1995;10: 1844-1852.
66. Johansson AG, Lindh E, Ljunghall S: Insulin-like growth factor I stimulates bone turnover in osteoporosis. Lancet 1992;339:1619.
67. Boonen S, Rosen C, Bouillon R, Sommer A, McKay M, Rosen D, Adams S, Vanderschueren D, Broos P, Lenaerts J, Raus J, Geusens P: Musculoskeletal effects of the recombinant human insulin-like growth factor-I (rhIGF-I)/IGF binding protein-3 (IGFBP-3) complex in osteo-porotic patients with proximal femoral fracture. A double-blind placebo-controlled pilot study. J Clin Endocr Metab 2002;87:1593-1599.
68. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.